Literature DB >> 984806

Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.

J N Galgiani, D A Stevens.   

Abstract

The current development of potent antifungal drugs necessitates reliable methods of in vitro susceptibility testing of clinical isolates. Other laboratories have noted with some antimicrobials that conventional tube dilution visual end points for determining minimal inhibitory concentrations (MIC) vary markedly with the inoculum. With seven isolates (four species) we compared the conventional method with one developed with a spectrophotometer. Yeasts were diluted to inocula of 10(2) to 10(5) cells/ml and incubated at 37 degrees C with 5-fluorocytosine or miconazole or without drug in a synthetic defined medium. At frequent intervals MICs were determined by the lowest drug concentration without visible turbidity. Concurrently, the percent transmission of each tube was measured and an inhibitory concentration (IC((1/2))) was calculated from the turbidimetric measurements. MICs of both drugs for all strains varied with the inoculum. Intrastrain differences averaged 128-fold for miconazole and greater than 8-fold with 5-fluorocytosine. This variability in MIC occurred when readings were made after 12 to 48 h of incubation. In contrast, IC((1/2)) values of all isolates varied less than two-fold with the same range of inocula. Most isolates showed this independence when measured at 48 h. Fast-growing yeasts showed greater IC((1/2)) variability unless the turbidimetric measurements were taken earlier while the drug-free growth was still in a rapid growth phase. This method is reproducible, inoculum independent, rapid, free from subjectivity and observer variability, and suitable for adaptation to a clinical setting.

Entities:  

Mesh:

Year:  1976        PMID: 984806      PMCID: PMC429820          DOI: 10.1128/AAC.10.4.721

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

Review 1.  Chemotherapy of systemic mycoses (first of two parts).

Authors:  J E Bennett
Journal:  N Engl J Med       Date:  1974-01-03       Impact factor: 91.245

2.  Obfuscation of the activity of antifungal antimicrobics by culture media.

Authors:  P D Hoeprich; P D Finn
Journal:  J Infect Dis       Date:  1972-10       Impact factor: 5.226

3.  The nature and control of infections in patients with acute leukemia.

Authors:  E Frei; R H Levin; G P Bodey; E E Morse; E J Freireich
Journal:  Cancer Res       Date:  1965-10       Impact factor: 12.701

4.  Patterns of Candida endocarditis following cardiac surgery: Importance of early diagnosis and therapy (an analysis of 91 cases).

Authors:  M S Seelig; C P Speth; P J Kozinn; C L Taschdjian; E F Toni; P Goldberg
Journal:  Prog Cardiovasc Dis       Date:  1974 Sep-Oct       Impact factor: 8.194

5.  A pharmacologic guide to the clinical use of amphotericin B.

Authors:  D D Bindschadler; J E Bennett
Journal:  J Infect Dis       Date:  1969-10       Impact factor: 5.226

6.  Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice.

Authors:  J D Hamilton; D M Elliott
Journal:  J Infect Dis       Date:  1975-02       Impact factor: 5.226

7.  Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine.

Authors:  E R Block; A E Jennings; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

  7 in total
  79 in total

1.  Comparison of three methods of determining MICs for filamentous fungi using different end point criteria and incubation periods.

Authors:  C Llop; I Pujol; C Aguilar; J Sala; D Riba; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

3.  In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method.

Authors:  M T Blanco; C Pérez-Giraldo; J Blanco; F J Morán; C Hurtado; A C Gómez-García
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

4.  Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test.

Authors:  J L Rodríguez-Tudela; J V Martinez-Suarez
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

5.  Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.

Authors:  J R Perfect; K A Wright; M M Hobbs; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy.

Authors:  K A McIntyre; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

7.  Effects of temperature on anti-Candida activities of antifungal antibiotics.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts.

Authors:  G V Doern; T A Tubert; K Chapin; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

9.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Authors:  C Quereda; A M Polanco; C Giner; A Sánchez-Sousa; E Pereira; E Navas; J Fortún; A Guerrero; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.